218 related articles for article (PubMed ID: 34210686)
1. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Jeannot E; Latouche A; Bonneau C; Calméjane MA; Beaufort C; Ruigrok-Ritstier K; Bataillon G; Larbi Chérif L; Dupain C; Lecerf C; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Jordanova ES; von der Leyen H; Tran-Perennou C; Legrier ME; Dureau S; Raizonville L; Bello Roufai D; Le Tourneau C; Bièche I; Rouzier R; Berns EMJJ; Kamal M; Scholl S
Clin Cancer Res; 2021 Nov; 27(21):5869-5877. PubMed ID: 34210686
[TBL] [Abstract][Full Text] [Related]
2. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.
Cabel L; Bonneau C; Bernard-Tessier A; Héquet D; Tran-Perennou C; Bataillon G; Rouzier R; Féron JG; Fourchotte V; Le Brun JF; Benoît C; Rodrigues M; Scher N; Minsat M; Legrier ME; Bièche I; Proudhon C; Sastre-Garau X; Bidard FC; Jeannot E
ESMO Open; 2021 Jun; 6(3):100154. PubMed ID: 34022731
[TBL] [Abstract][Full Text] [Related]
3. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay.
Galati L; Combes JD; Le Calvez-Kelm F; McKay-Chopin S; Forey N; Ratel M; McKay J; Waterboer T; Schroeder L; Clifford G; Tommasino M; Gheit T
Microbiol Spectr; 2022 Apr; 10(2):e0148021. PubMed ID: 35225653
[TBL] [Abstract][Full Text] [Related]
4. Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
Han K; Zou J; Zhao Z; Baskurt Z; Zheng Y; Barnes E; Croke J; Ferguson SE; Fyles A; Gien L; Gladwish A; Lecavalier-Barsoum M; Lheureux S; Lukovic J; Mackay H; Marchand EL; Metser U; Milosevic M; Taggar AS; Bratman SV; Leung E
J Clin Oncol; 2024 Feb; 42(4):431-440. PubMed ID: 37972346
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy of HPV DNA in cervical cancer.
Cheung TH; Yim SF; Yu MY; Worley MJ; Fiascone SJ; Chiu RWK; Lo KWK; Siu NSS; Wong MCS; Yeung ACM; Wong RRY; Chen ZG; Elias KM; Chung TKH; Berkowitz RS; Wong YF; Chan PKS
J Clin Virol; 2019 May; 114():32-36. PubMed ID: 30913520
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients.
Campitelli M; Jeannot E; Peter M; Lappartient E; Saada S; de la Rochefordière A; Fourchotte V; Alran S; Petrow P; Cottu P; Pierga JY; Lantz O; Couturier J; Sastre-Garau X
PLoS One; 2012; 7(8):e43393. PubMed ID: 22937045
[TBL] [Abstract][Full Text] [Related]
7. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
Chera BS; Kumar S; Shen C; Amdur R; Dagan R; Green R; Goldman E; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Blumberg J; Patel S; Thorp B; Weissler M; Yarbrough W; Sheets N; Mendenhall W; Tan XM; Gupta GP
J Clin Oncol; 2020 Apr; 38(10):1050-1058. PubMed ID: 32017652
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.
Cabel L; Jeannot E; Bieche I; Vacher S; Callens C; Bazire L; Morel A; Bernard-Tessier A; Chemlali W; Schnitzler A; Lièvre A; Otz J; Minsat M; Vincent-Salomon A; Pierga JY; Buecher B; Mariani P; Proudhon C; Bidard FC; Cacheux W
Clin Cancer Res; 2018 Nov; 24(22):5767-5771. PubMed ID: 30054279
[No Abstract] [Full Text] [Related]
9. HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
Veyer D; Wack M; Mandavit M; Garrigou S; Hans S; Bonfils P; Tartour E; Bélec L; Wang-Renault SF; Laurent-Puig P; Mirghani H; Rance B; Taly V; Badoual C; Péré H
Int J Cancer; 2020 Aug; 147(4):1222-1227. PubMed ID: 31756275
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia.
Persson M; Brismar Wendel S; Ljungblad L; Johansson B; Weiderpass E; Andersson S
Oncol Rep; 2012 Jul; 28(1):346-52. PubMed ID: 22484610
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker.
Widschwendter A; Blassnig A; Wiedemair A; Müller-Holzner E; Müller HM; Marth C
Cancer Lett; 2003 Dec; 202(2):231-9. PubMed ID: 14643453
[TBL] [Abstract][Full Text] [Related]
12. Plasma Cell-Free Human Papillomavirus Oncogene E6 and E7 DNA Predicts Outcome in Oropharyngeal Squamous Cell Carcinoma.
Reder H; Taferner VF; Wittekindt C; Bräuninger A; Speel EM; Gattenlöhner S; Wolf G; Klussmann JP; Wuerdemann N; Wagner S
J Mol Diagn; 2020 Nov; 22(11):1333-1343. PubMed ID: 32822851
[TBL] [Abstract][Full Text] [Related]
13. Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarker.
Rungkamoltip P; Temisak S; Piboonprai K; Japrung D; Thangsunan P; Chanpanitkitchot S; Chaowawanit W; Chandeying N; Tangjitgamol S; Iempridee T
Exp Biol Med (Maywood); 2021 Mar; 246(6):654-666. PubMed ID: 33307803
[TBL] [Abstract][Full Text] [Related]
14. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer.
Ferrier ST; Tsering T; Sadeghi N; Zeitouni A; Burnier JV
Cancer Med; 2023 Aug; 12(15):15777-15787. PubMed ID: 37526056
[TBL] [Abstract][Full Text] [Related]
15. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free HPV DNA is a strong marker for disease severity in cervical cancer.
Bønløkke S; Steiniche T; Sorensen BS; Nyvang GB; Lindegaard JC; Blaakær J; Bertelsen J; Fuglsang K; Strube ML; Lenz S; Stougaard M
Mol Oncol; 2024 May; 18(5):1231-1244. PubMed ID: 37853962
[TBL] [Abstract][Full Text] [Related]
18. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
[TBL] [Abstract][Full Text] [Related]
19. Circulating Cell-free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring.
Kang Z; Stevanović S; Hinrichs CS; Cao L
Clin Cancer Res; 2017 Nov; 23(22):6856-6862. PubMed ID: 28899967
[No Abstract] [Full Text] [Related]
20. [Biomarkers of cervical carcinogenesis associated with genital human papillomavirus infection].
Oliveira A; Delgado C; Verdasca N; Pista A
Acta Med Port; 2013; 26(2):139-44. PubMed ID: 23809746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
